Poseida Therapeutics Inc

Poseida Therapeutics — Investor Presentation (August 2022)

16 slides from Poseida Therapeutics's investor presentation, Aug 3, 2022

  1. Slide 1: The Next Wave of Cell and Gene Therapies with the Capacity to Cure

    Exhibit 99.2 The Next Wave of Cell and Gene Therapies with the Capacity to Cure August 3, 2022

  2. Slide 2: Disclaimer

    Disclaimer This presentation and any accompanying oral commentary contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and include, without limitation, statem

  3. Slide 3: On a Mission to Redefine Cell and Gene Therapy

    CELL THERAPY CAR-T Therapy for Oncology Focusing on Fully Allogeneic CAR-T PLATFORMS & On a Mission to Redefine PARTNERSHIPS Cell and Gene Therapy For Platform Patients with Cancer, Rare GENE THERAPY Development, In Vivo Liver-Directed Partnerships and Diseases and Beyond Gene Therapy Collaboration

  4. Slide 4: We Are the Next Wave of Genetic Engineering

    We Are the Next Wave of Genetic Engineering Broad differentiated in-house technology platforms have the potential to develop treatments in many therapeutic segments and disease indications. Nanoparticles Super piggyBac® Cas-CLOVER™ AAV Vectors • Highly precise site-specific • Non-viral system • Deli

  5. Slide 5: Disruptive Innovation in CAR-T

    Disruptive Innovation in CAR-T Allogeneic CAR-T Therapy for Oncology Cell Type Matters Fully Allogeneic CAR-T Cost, Scale & Reach T Cell Stem Cell Memory SCM • Self-renewing MHC I knock-out • Long lived TCR knock-out • Multipotent T is the ideal cell type for CAR-T Addressing both Graft v Host Boost

  6. Slide 6: Disruption in Gene Therapy

    Disruption in Gene Therapy In Vivo Gene Therapy for Rare Diseases and Hard-to-Treat Juvenile Populations Fully Integrating Broad Application Addressing Challenges of Viral Delivery piggyBac integrates into piggyBac cargo capacity DNA enabling the potential addresses more indications piggyBac and Nan

  7. Slide 7: Announcing Our Global Partnership with Roche

    Announcing Our Global Partnership with Roche* Broad Platform Technology Delivers Powerful Strategic Partnerships ALLOGENEIC CELL THERAPY FOR ONCOLOGY Partnership with Roche focused on allogeneic CAR-T for heme malignancies Strong innovation engine and powerful platform technologies may enable PLATFO

  8. Slide 8: Roche Partnership: Strategic Rationale

    ALLOGENEIC CELL THERAPY FOR ONCOLOGY Partnership with Roche focused on Strategic Rationale allogeneic CAR-T for heme malignancies • Roche is one of the most scientifically discerning companies in pharma and a leader in oncology and hematologic malignancies • Broad scope across hematologic malignanci

  9. Slide 9: Roche Partnership: Collaboration Scope

    ALLOGENEIC CELL THERAPY FOR ONCOLOGY Partnership with Roche focused on Collaboration Scope allogeneic CAR-T for heme malignancies • Broad strategic partnership in allogeneic CAR-T for hematologic malignancies • Exclusive license to P-BCMA-ALLO1 and P-CD19CD20-ALLO1 programs • Exclusive option to P-C

  10. Slide 10: Roche Partnership: Economic Summary

    ALLOGENEIC CELL THERAPY FOR ONCOLOGY Partnership with Roche focused on Economic Summary allogeneic CAR-T for heme malignancies • Upfront payment of $110 million expected to be received in 2H 2022 • Up to $110 million in near-term fees and milestone and other payments Poseida believes are highly achi

  11. Slide 11: Cell Therapy Pipeline

    Cell Therapy Pipeline Primary Focus on Allogeneic CAR-T for Solid and Liquid Tumors Indication Candidate Discovery Preclinical IND-Enabling Phase 1 Phase 2 CAR-T FOR ONCOLOGY P-MUC1C-ALLO1 Allo P-PSMA-101 Auto SOLID TUMOR P-PSMA-ALLO1 Allo DUAL UNDISCLOSED Allo P-BCMA-ALLO1 Allo MULTIPLE MYELOMA P-B

  12. Slide 12: Strategic Partnership with Takeda in In Vivo Gene Therapy

    Strategic Partnership with Takeda in In Vivo Gene Therapy Partnership in Liver- and HSC- Directed In Vivo Gene Therapy with Takeda Validates Approach, Generates Resources – While Preserving Large Gene Therapy Opportunity for Poseida • Poseida retains rights to P-OTC-101 and all • Strategic Partnersh

  13. Slide 13: Gene Therapy Pipeline

    Gene Therapy Pipeline In Vivo Liver-Directed and HSC- Directed Gene Therapy Indication Candidate Discovery Preclinical IND-Enabling GENE THERAPIES ORNITHINE TRANSCARBAMYLASE P-OTC-101 DEFICIENCY (OTC) Rare Liver Disorder TBA HEMOPHILIA A P-FVIII-101 3 UNDISCLOSED LIVER-DIRECTED PROGRAMS 2 UNDISCLOSE

  14. Slide 14: We're Just Beginning to Tap the Potential

    We’re Just Beginning to Tap the Potential Strategic Partnerships Power Our Pipeline, Validate Our Unique Technology in Multiple Segments, and Support Ongoing Platform Innovation GENE THERAPIES CELL THERAPIES AAV-PB & Nano-PB Allogeneic CAR-T/TCR-T LIVER, HSC, LUNG, CNS, ONCOLOGY ETC. In Vivo EP Curr

  15. Slide 15: Focused on Key Priorities to Drive Value Creation

    Focused on Key Priorities to Drive Value Creation Working to Create Single-Treatment Cures for Cancer, Genetic Diseases and Beyond CELL THERAPY • Strong Validating and Empowering Strategic CAR-T Therapy for Collaborations and Partnership with Roche and Oncology Focusing on Fully Allogeneic CAR-T Tak

  16. Slide 16: Thank You

    Thank You The Next Wave of Cell & Gene Therapies with the Capacity to Cure

Poseida Therapeutics — Investor Presentation (August 2022) on 6ix